Figure 1.
Flow of participants through the main 6‐month period of the EDITION JP 1 study [modified intention‐to‐treat (mITT) and safety populations]. Gla‐100, insulin glargine 100 U/ml; Gla‐300, insulin glargine 300 U/ml.
Flow of participants through the main 6‐month period of the EDITION JP 1 study [modified intention‐to‐treat (mITT) and safety populations]. Gla‐100, insulin glargine 100 U/ml; Gla‐300, insulin glargine 300 U/ml.